| Issuer | % of Class | Filed |
|---|---|---|
|
CytoMed Therapeutics Ltd
13D/A
Amendment 5
GDTC · Y1R80M106
|
25.2% |
10/16/2026
Event 10/12/2026
|
|
CytoMed Therapeutics Ltd
13D/A
Amendment 4
GDTC · Y1R80M106
|
24.9% |
10/13/2026
Event 10/6/2026
|
|
CytoMed Therapeutics Ltd
13D/A
Amendment 3
GDTC · Y1R80M106
|
24.3% |
7/24/2026
Event 7/20/2026
|
|
CytoMed Therapeutics Limited
13D/A
Amendment 2
GDTC · Y1R80M106
|
22.1% |
10/29/2025
Event 10/29/2025
|
|
CytoMed Therapeutics Ltd
13D/A
Amendment 1
GDTC · Y1R80M106
|
23.2% |
3/14/2025
Event 2/20/2025
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.